Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $163
J&J Submits Supplemental BLA for Darzalex Faspro to FDA
Johnson & Johnson Submits Application to FDA for Multiple Myeloma Treatment
J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program -- WSJ
Express News | Johnson & Johnson Files for U.S. FDA Approval of Darzalex Faspro®-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned
80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024
Johnson & Johnson Price Target Maintained With a $215.00/Share by Cantor Fitzgerald
Johnson & Johnson Analyst Ratings
Cantor Fitzgerald Remains a Buy on Johnson & Johnson (JNJ)
Express News | J&J - Expands Roll-Out of Latest Advancement in Presbyopia-Correcting Intraocular Lenses (PC - Iol), Tecnis Odyssey, in U.S.
Johnson & Johnson Says Blood Cancer Therapy Significantly Extends Overall Survival in Patients
Express News | Janssen-Cilag International NV: European Commission Approves Yuvanci®for Treatment of Patients With Pulmonary Arterial Hypertension (Pah)
Johnson & Johnson (JNJ): Hedge Funds Bet Big on Healthcare Giant Amid 4.3% Q2 Revenue Increase
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
J&J, Legend Report Carvykti Cut Death Risk by 45% in Multiple Myeloma Study
J&J Releases Encouraging Data on Talvey Combination Therapies
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Express News | J&J: 45 Percent Reduction in Risk of Death Achieved With Carvykti(®) After Three-Year Follow-up in Landmark Cartitude-4 Study
Express News | Carvykti® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients With Multiple Myeloma as Early as Second Line
Johnson & Johnson: Cepheus Phase 3 Study Shows Improvement for Patients With Multiple Myeloma